These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17062205)

  • 41. Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: importance of early use.
    Tasouli A; Papadopoulos K; Antoniou T; Kriaras I; Stavridis G; Degiannis D; Geroulanos S
    Eur J Cardiothorac Surg; 2007 Oct; 32(4):629-33. PubMed ID: 17702589
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mechanisms of a reduced cardiac output and the effects of milrinone and levosimendan in a model of infant cardiopulmonary bypass.
    Stocker CF; Shekerdemian LS; Nørgaard MA; Brizard CP; Mynard JP; Horton SB; Penny DJ
    Crit Care Med; 2007 Jan; 35(1):252-9. PubMed ID: 17133188
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Levosimendan--an inoprotective drug or much ado about nothing?
    Lehmann A; Radke J; Sack FU
    Crit Care Med; 2011 Oct; 39(10):2365-6. PubMed ID: 21926495
    [No Abstract]   [Full Text] [Related]  

  • 44. Planned repetitive use of levosimendan for heart failure in cardiology and internal medicine in Sweden.
    Thorvaldsen T; Benson L; Hagerman I; Dahlström U; Edner M; Lund LH
    Int J Cardiol; 2014 Jul; 175(1):55-61. PubMed ID: 24820737
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pre-operative use of levosimendan in two patients with severe aortic stenosis and left ventricular dysfunction.
    Prior DL; Flaim BD; MacIsaac AI; Yii MY
    Heart Lung Circ; 2006 Feb; 15(1):56-8. PubMed ID: 16473793
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure.
    Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
    Int J Clin Pharmacol Ther; 2002 Oct; 40(10):465-71. PubMed ID: 12395979
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
    Drakos SG; Kanakakis JV; Nanas S; Bonios M; Kaldara E; Katsaros F; Pantsios C; Nanas JN
    J Cardiovasc Pharmacol; 2009 Feb; 53(2):157-61. PubMed ID: 19188832
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure.
    Duygu H; Ozerkan F; Zoghi M; Nalbantgil S; Yildiz A; Akilli A; Akin M; Nazli C; Ergene O
    Int J Clin Pract; 2008 Feb; 62(2):228-33. PubMed ID: 17949428
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Timing of levosimendan in cardiac surgery.
    Aksun M; Karahan N; Adanir T; Aran G; Yetkin U; Oztürk T; Sencan A; Ozgürbüz U; Gürbüz A
    Anadolu Kardiyol Derg; 2009 Jun; 9(3):223-30. PubMed ID: 19520657
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intracoronary levosimendan prevents myocardial ischemic damages and activates survival signaling through ATP-sensitive potassium channel and nitric oxide.
    Caimmi PP; Molinari C; Uberti F; Micalizzi E; Valente G; Mary DA; Vacca G; Grossini E
    Eur J Cardiothorac Surg; 2011 Apr; 39(4):e59-67. PubMed ID: 21247774
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral levosimendan improves filling pressure and systolic function during long-term treatment.
    Jalanko M; Kivikko M; Harjola VP; Nieminen MS; Laine M
    Scand Cardiovasc J; 2011 Apr; 45(2):91-7. PubMed ID: 21348810
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Experiences of levosimendan as an inotropic agent in conjunction with passive containment surgery.
    Bredin F; Franco-Cereceda A
    Scand Cardiovasc J; 2007 Jun; 41(3):197-200. PubMed ID: 17487771
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pulsed levosimendan therapy in the management of chronic end stage cardiac failure in 'adult congenital heart disease'.
    Rafiq I; Freeman LJ
    Int J Cardiol; 2015 Sep; 195():283-4. PubMed ID: 26056958
    [No Abstract]   [Full Text] [Related]  

  • 54. Can we believe in levosimendan?
    Follath F
    Arq Bras Cardiol; 2008 Mar; 90(3):146-7. PubMed ID: 18392391
    [No Abstract]   [Full Text] [Related]  

  • 55. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting.
    Lilleberg J; Nieminen MS; Akkila J; Heikkilä L; Kuitunen A; Lehtonen L; Verkkala K; Mattila S; Salmenperä M
    Eur Heart J; 1998 Apr; 19(4):660-8. PubMed ID: 9597417
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Orally available levosimendan dose-related positive inotropic and lusitropic effect in conscious chronically instrumented normal and heart failure dogs.
    Masutani S; Cheng HJ; Hyttilä-Hopponen M; Levijoki J; Heikkilä A; Vuorela A; Little WC; Cheng CP
    J Pharmacol Exp Ther; 2008 Apr; 325(1):236-47. PubMed ID: 18174383
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Levosimendan in decompensated heart failure patients: efficacy in a Brazilian cohort. Results of the BELIEF study.
    Bocchi EA; Vilas-Boas F; Moreira Mda C; Barretto AC; Lage S; Albuquerque D; Baima J; Rassi S; Ribeiro JP; ;
    Arq Bras Cardiol; 2008 Mar; 90(3):182-90. PubMed ID: 18392398
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy.
    Pölzl G; Altenberger J; Baholli L; Beltrán P; Borbély A; Comin-Colet J; Delgado JF; Fedele F; Fontana A; Fruhwald F; Giamouzis G; Giannakoulas G; Garcia-González MJ; Gustafsson F; Kaikkonen K; Kivikko M; Kubica J; von Lewinski D; Löfman I; Malfatto G; Manito N; Martínez-Sellés M; Masip J; Merkely B; Morandi F; Mølgaard H; Oliva F; Pantev E; Papp Z; Perna GP; Pfister R; Piazza V; Bover R; Rangel-Sousa D; Recio-Mayoral A; Reinecke A; Rieth A; Sarapohja T; Schmidt G; Seidel M; Störk S; Vrtovec B; Wikström G; Yerly P; Pollesello P
    Int J Cardiol; 2017 Sep; 243():389-395. PubMed ID: 28571618
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Repeated or intermittent levosimendan treatment in advanced heart failure: An updated meta-analysis.
    Silvetti S; Nieminen MS
    Int J Cardiol; 2016 Jan; 202():138-43. PubMed ID: 26386941
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one], dobutamine, and milrinone: comparative effects on peripheral resistance, cardiac output, dP/dt, pulse rate, and blood pressure.
    Segreti JA; Marsh KC; Polakowski JS; Fryer RM
    J Pharmacol Exp Ther; 2008 Apr; 325(1):331-40. PubMed ID: 18171907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.